Generate Biomedicines (NASDAQ:GENB) Shares Up 8.4% - Should You Buy?

Key Points

• Generate Biomedicines shares rose 8.4% to $17.00 in midday trading, although volume was 82% below the stock’s average daily level.
• Analyst sentiment is mixed but leans positive: six analysts rate the stock a Buy, one rates it Hold and one Sell, producing a consensus “Moderate Buy” rating and a $26.40 price target.
• The company reported a quarterly loss of $0.52 per share, missing estimates by $0.04, and analysts expect a full-year loss of $2.29 per share. Several institutional investors nevertheless initiated positions during the second quarter.

Generate Biomedicines Inc (NASDAQ:GENB - Get Free Report) shares were up 8.4% on Thursday . The company traded as high as $16.95 and last traded at $17.00. 145,986 shares changed hands during mid-day trading, a decline of 82% from the average daily volume of 796,735 shares. The stock had previously closed at $15.68.

Wall Street Analyst Weigh In

GENB has been the topic of a number of recent research reports. HC Wainwright reissued a "buy" rating and set a $30.00 price target on shares of Generate Biomedicines in a research note on Tuesday, September 8th. Weiss Ratings began coverage on shares of Generate Biomedicines in a report on Tuesday, August 11th. They issued a "sell (d)" rating on the stock. Finally, Wall Street Zen cut Generate Biomedicines from a "hold" rating to a "sell" rating in a research note on Saturday, September 12th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $26.40.

Generate Biomedicines Price Performance

The firm has a market capitalization of $2.20 billion and a P/E ratio of -10.79. The firm's fifty day moving average is $15.12.

Generate Biomedicines (NASDAQ:GENB - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.04). The business had revenue of $6.31 million during the quarter. On average, sell-side analysts predict that Generate Biomedicines Inc will post -2.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Generate Biomedicines

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Braidwell LP bought a new position in shares of Generate Biomedicines in the second quarter valued at approximately $55,398,000. The Manufacturers Life Insurance Company bought a new position in shares of Generate Biomedicines in the second quarter worth $1,431,000. Bank of New York Mellon Corp bought a new stake in Generate Biomedicines during the second quarter valued at $967,000. Squarepoint Ops LLC bought a new position in Generate Biomedicines in the 2nd quarter worth about $530,000. Finally, AXQ Capital LP bought a new stake in shares of Generate Biomedicines during the 2nd quarter valued at about $218,000.

Generate Biomedicines Company Profile

Generate Biomedicines is a biotechnology company that uses generative artificial intelligence and machine learning to discover and design protein-based medicines. Its technology is intended to model relationships among protein sequences, structures and biological functions, helping researchers create therapeutic proteins with desired characteristics.

The company's research activities are focused on developing novel biologic medicines for areas of significant unmet medical need, including oncology, immunology, infectious diseases and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.